The use of pituitary cell type-specific promoters is a powerful molecular tool to achieve pituitary cell type-specific transcriptional targeting of transgenes encoded by viral vectors. It has recently been proposed that transcriptional targeting of therapeutic genes could be harnessed as a gene therapy strategy for the treatment of pituitary disease. We describe the successful use of the human PRL promoter (hPrl) encoded within recombinant adenovirus vectors to target transgene expression of Herpes Simplex Virus Type 1-Thymidine Kinase (HSV1-TK) or ␤-galactosidase to lactotrophic cells in vitro and in vivo. Functionally, the restriction of expression of HSV1-TK to lactotrophic tumor cells, using the hPrl promoter, resulted in the cell type-specific induction of apoptosis in the lactotrophic GH3 tumor cell line, in the presence of ganciclovir (GCV). In the corticotrophic AtT20 cell line, we detected neither HSV1-TK expression, nor apoptosis in the presence of GCV. The hPrl promoter encoded within a recombinant adenoviral vector also restricted transgene expression to lactotrophic cells in primary anterior pituitary (AP) cultures, and importantly, within the anterior pituitary gland in vivo. When the HSV1-TK driven by hPrl promoter was used in an in vivo model of estrogen/sulpiride lactotroph induced hyperplasia within the AP in situ, the treatment was not effective in either reducing the weight of the gland, the number of lactotrophic cells within the transduced area in vivo, or the circulating PRL levels. This is in contrast to the human cytomegalovirus promoter (hCMV) driving expression of HSV1-TK in the same experimental paradigm, which was effective in reducing pituitary weight and circulating PRL levels. Our results have important implications in the design of gene therapy strategies for pituitary tumors. We demonstrate that both the choice of the in vivo animal model, i.e. adenoma in the AP gland in situ, and the particular gene therapy strategy chosen, i.e. use of strong ubiquitous promoters vs. weaker but cell type-specific promoters, determine the experimental therapeutic outcome. (Endocrinology 141: [3493][3494][3495][3496][3497][3498][3499][3500][3501][3502][3503][3504][3505] 2000) 
M ANY DISEASES that affect pituitary function remain
poorly treated by currently available therapeutic strategies. One reason for this is the multiplicity of transcriptional, posttranscriptional, hormonal, and neurotransmitter controls that affect the function of individual pituitary cell types. Drugs used to regulate anterior pituitary function lack the capacity to discriminate between different pituitary cell types, or even between normal and tumoral cells. Further, the levels of circulating hormones given as replacement for pituitary hormone deficiencies cannot be finely tuned, as endogenous hormones normally are. One way of overcoming some of these limitations is the development of gene therapy (1) . The development of pituitary cell type-specific vectors should allow endogenous promoters to drive expression of a variety of therapeutic transgenes, either for hormone replacement, or to selectively modify the function of a particular cell type (2, 3) . The use of cell type-specific promoters would allow transgene expression to be maintained under the control of the endogenous physiological regulators. A particular implementation of this strategy would be the use of cell type-specific promoters to eliminate tumors originating from a specific pituitary cell type. The pituitary lactotrophic cell was chosen as a target for this work both because of the availability of specific promoter sequences and because of the existence of well characterized in vitro and in vivo model systems in which to test their function.
A 5,000-bp human PRL promoter (hPrl) has been extensively studied and shown to allow pituitary-specific expression (4, 5) . The specificity of the rat PRL promoter has been demonstrated in vivo using transgenic mice (6) . The proximal region of the promoter (ϩ33bp to Ϫ422 bp) is sufficient to provide lactotroph specific expression; the distal region (Ϫ1500 bp to Ϫ1800 bp) is required for high levels of expression. For this reason, we have decided to use the ϩ14 bp to Ϫ4429 bp sequences containing the proximal element (Ϫ40 bp to Ϫ250 bp), the distal element (Ϫ1300 bp to Ϫ1700 bp), and a portion of the super distal region (Ϫ3500 bp to Ϫ5000 bp) of hPrl promoter for our studies. Castro et al. (1997) (7) were the first to demonstrate the feasibility of using both adenoviruses and herpes simplex type-1 vectors to transfer genes into anterior pituitary cells in primary culture (8) . We have also recently used herpes simplex type-1 thymidine kinase (HSV1-TK) encoded within a replication defective adenovirus vector under the control of a strong ubiquitous promoter (hCMV) to successfully inhibit pituitary lactotroph hyperplasia and reduce circulating PRL levels in an animal model (9) .
In this paper, we demonstrate lactotrophic cell typespecific expression of the marker gene ␤-galactosidase, and the conditional cytotoxic gene HSV1-TK, both driven by the hPrl promoter and encoded within recombinant adenovirus vectors. Cell type-specific expression was demonstrated in anterior pituitary tumor cell lines, anterior pituitary cells in primary culture, and the pituitary gland in vivo. Our results show, for the first time, transcriptional targeting of a marker transgene (␤-galactosidase), as well as the therapeutic transgene HSV1-TK, to a predetermined endocrine cell population within the AP gland in vivo.
When an adenovirus vector encoding HSV1-TK driven by the hPrl promoter was used in an in vivo model of estrogen/ sulpiride induced lactotroph hyperplasia within the anterior pituitary (AP) gland in situ, the infection of the AP gland combined with the administration of ganciclovir, was not able to reduce neither the weight of the gland, the number of lactotrophic cells in vivo, nor the circulating PRL levels. This is in contrast to the use of an adenovirus expressing HSV1-TK under the transcriptional control of the human cytomegalovirus promoter (hCMV), employed in the same experimental paradigm. Such a vector, in combination with ganciclovir, was effective in reducing pituitary weight and also circulating PRL levels. Therefore, our results highlight that further engineering of these cell type-specific promoters will be needed to develop effective cell type-specific gene therapy strategies for the treatment of pituitary tumors using transcriptional targeted approaches.
Our results also have important implications for the design of gene therapy strategies for pituitary tumors. Our data demonstrate that both the choice of the in vivo animal model (e.g. anterior pituitary adenoma in situ vs. transplantable tumors), as well as the gene therapy strategy chosen (e.g. use of strong ubiquitous promoters vs. weaker but cell typespecific promoters), does influence the therapeutic outcome.
Materials and Methods

Cell lines and culture conditions
All cell culture reagents were purchased from Sigma (Poole, Dorset, UK) or Life Technologies, Inc. (Paisley, UK). All tissue culture plasticware was purchased from Greiner (Stonehouse, Gloustershire, UK). AtT20 cells (provided by Dr. F. Antoni, Medical Research Council Brain Metabolism Unit, Department of Pharmacology, University of Edinburgh, Scotland, UK), and GH3 cells (by Dr. S. Cockle, Department of Biochemistry and Physiology, University of Reading, Reading, UK), were grown in DMEM supplemented with sodium pyruvate (1 mm), glutamine (2 mm), nonessential amino acids (0.2 mm), 10% (vol/vol) horse serum, and 5% (vol/vol) newborn calf serum at 37 C in a 5% CO 2 atmosphere. This medium will be referred to as complete growth medium. Rat AP primary cell cultures were prepared as described previously (7).
Reagents and antibodies
Different cell types within the AP cultures were identified using the following polyclonal antibodies: guinea-pig antirat ␤-TSH (1/100), guinea-pig antirat PRL (1/500), guinea-pig antirat ␤-LH (1/100), guinea-pig antihuman GH (1/500), sheep antihuman ␤-FSH (1/500), and sheep antihuman ACTH (1/500) (provided by NIDDK's National Hormone and Pituitary Program, Bethesda, MD). The antibody used to identify ␤-galactosidase was a rabbit polyclonal anti-␤-galactosidase (1/750) (9); rabbit anti-HSV1-TK antibody (1/1000) was kindly provided by M. Janicot, Rhone-Poulenc-Rorer, France (10, 11) .
Secondary antibodies used for either single or double immunolabeling were FITC or Texas Red-donkey antirabbit and FITC or Texas Redgoat anti-guinea-pig from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA).
Generation of recombinant adenoviruses expressing transgenes under the control of the human PRL promoter
The transgenes, HSV1-TK and ␤-galactosidase, were excised from the plasmids pMV60/HSV1-TK (10) and pMV12/lacZ (12) by BamHI digestion and cloned into a plasmid derived from pGEM9ZF (Promega Corp., Madison, WI), that contained the neuronal specific enolase (NSE) promoter and the SV40 polyA generating pGEM9ZF/NSE/HSV1-TK/ polyA and pGEM9ZF/NSE/lacZ/polyA. The HSV1-TK/polyA and lacZ/polyA cassettes were excised from these plasmids by NspV/XhoI digestion and the NspV site adapted to NcoI using a linker. The adapted fragments were then cloned into the p5000 plasmid, containing the 5kb hPRl, in the NcoI/XhoI sites (13) . The hPrl/HSV1-TK/polyA cassette was excised by XbaI/XhoI digestion and cloned into the XbaI/SalI site in p⌬E1sp1a (Microbix Biosystems, Toronto, Ontario, Canada). The hPrl/lacZ/polyA cassette was excised by MunI/XhoI digestion and cloned into the EcoRI/XhoI site in p⌬E1sp1a.
RAds were generated by cotransfection using the calcium phosphate coprecipitation method (14) with each shuttle vector and pBHG10 (Microbix Biosystems), and purified using double cesium chloride gradient as previously described (15) . Viral DNA was obtained as described by Revah et al., 1996 (16) . To confirm the presence of the transgenes, viral DNA digestion with HindIII and subsequent Southern blot hybridization was performed. The specific probes used were: the 2982 bp lacZ fragment excised using BamHI (ϩ5033 to ϩ8015) from p5000/hPrl/lacZ, and the 1131 bp HSV1-TK fragment excised using BamHI (ϩ5033 to ϩ6164) from p5000/hPrl/HSV1-TK. The probes were labeled by random priming with digoxigenin-dUTP as described by the manufacturers (Roche Molecular Biochemicals, Bell Lane, East Sussex, UK).
The RAd-hCMV/HSV1-TK (RAd128), and RAd-hCMV/␤-gal, (RAd35) have been described in detail previously (10 -12) . RAd-mCMV/ ␤-gal (RAd36) was constructed using the murine CMV promoter (Ϫ1336 to ϩ36 bp) (17) driving the expression of the marker gene ␤-galactosidase. RAd stocks were assayed and shown to be negative, for the presence of replication competent adenovirus or endotoxin (lipopolysaccharide) as previously described (18, 19 GH3 and AtT20 cells were infected at multiplicity of infection (MOI) (number of infectious virus particles/cell) 30 with RAd35, RAd36, or RAd-Prl/lacZ. The cells were incubated for a further 2 days and X-gal histochemistry was performed as described previously (7) .
Enzymatic activity was tested by infecting GH3 and AtT20 cells at A, The 3,257-bp band of lacZ/polyA was detected using a labeled lacZ probe; B, the 1,406-bp band of HSV1-TK/polyA is detected using a labeled HSV1-TK probe; and C, the 5,000-bp band of mCMV/lacZ/polyA was detected using a mCMV/lacZ/polyA labeled probe. 
Cell type-specific expression of HSV1-TK and apoptosis in pituitary tumor cell lines
GH3 and AtT20 cells were infected with RAdPrl/HSV1-TK at an MOI 30 for 48 h. The virus was then removed, and fresh medium was added. The cells were then incubated for a further 2 days. HSV1-TK transgene expression was assessed using immunofluorescence techniques as described previously (7) . Cellular nuclei were stained using 4,6-diamidino-2-phenylindole (DAPI).
Simultaneous detection of HSV1-TK protein and cellular DNA content within GH3 and AtT20 cells following infection with RAd-Prl/ HSV-TK was performed by flow cytometry as described previously (9) . Fifty thousand cells were plated in six-well plates and infected with RAdPrl/HSV1-TK at increasing MOI (0, 1, 5, 20, 50, and 100). Experiments were performed twice. After 48 h infection, the cells were fed with complete growth medium containing 10 m ganciclovir (GCV; Roche Molecular Biochemicals, Welwyn Garden City, UK) and incubated for a further 72 h. Cells were harvested and then processed for DNA content and HSV1-TK immunoreactivity as described previously (9, 20, 21) .
Infection and detection of HSV1-TK within endocrine cells in primary AP cultures
AP cells were infected with RAd-Prl/HSV1-TK at an MOI 30, and incubated for 48 h. The virus was removed, fresh complete growth medium was added, and the primary cultures were incubated for 3 additional days. Colocalization of the HSV1-TK transgene within specific cell types present within the primary AP culture was assessed using immunofluorescence techniques as described previously (9); the cellular nuclei were stained using DAPI. For the quantification of endocrine and/or transduced cell types in vitro, 10 random fields within each well were counted.
Animals
Male 8-week-old Buffalo rats were house bred at the University of Manchester Biological Safety Unit. All animals had free access to food and water, a 12-h light, 12-h dark cycle, and constant housing temperature and humidity. Experiments were conducted according to the United Kingdom Animal (Scientific Procedures) Act of 1986.
FIG. 2. Histochemical analysis of ␤-galactosidase expression in GH3
and AtT20 tumor cell lines. Tumor cell lines were infected with RAdhCMV/lacZ, RAd-mCMV/lacZ, or RAd-Prl/lacZ at MOI 30. Two days later, the cells were stained using X-gal histochemistry and analyzed using light microscopy. Magnification, ϫ10.
FIG. 3.
Quantitative analysis of ␤-galactosidase enzyme activity in pituitary tumor cell lines. AtT20 or GH3 cells were infected with increasing MOIs of RAd-hCMV/lacZ, RAd-mCMV/lacZ, or RAd-Prl/ lacZ. Two days later, the cells were harvested and tested for ␤-galactosidase activity. These results were then corrected using the number of cells present in the cultures and transgene expression is shown as ␤-galactosidase enzymatic activity (units: U) per cell (mean Ϯ SEM; n ϭ 4).
In vivo gene delivery to the anterior pituitary gland
Male 8-week-old Buffalo rats (house bred) were anesthetized with halothane and placed in a sterotaxic frame. The skull was exposed, bregma was identified, and a hole was drilled posterior to bregma until revealing the superior sagittal sinus, and surrounding brain. A thin surgical suture was passed underneath the vein, and the meninges surrounding the vein were cut to allow the vein to be displaced laterally without lesioning the vein wall or the surrounding cortex. Intrapituitary injections were made using a 26-gauge Hamilton syringe needle. The tip of the needle had been previously ground until the opening of the needle was positioned at the base of the tip. Injections were made at the following coordinates: antero-posterior from Bregma, Ϫ0.57, Ϫ0.60, and Ϫ0.63 cm, and lateral on each side of the midline at 0.05 cm. Thus, we made a total of six injections per pituitary gland. Previous attempts to inject directly into the pituitary using exclusively stereotaxic coordinates failed in reliably delivering directly the RAds into the gland. Thus, we developed a modified strategy as follows: the modified Hamilton needle was lowered at each coordinate until touching the sphenoidal bone, and making contact with the bottom of the rat equivalent of the sella turcica. This leaves the opening of the needle within the pituitary gland, and adequate amounts of recombinant vector were then injected. Under these conditions of injection, the pituitary was transduced by recombinant adenoviruses in 100% of surgical attempts. At each of these six coordinates, 1 l of the recombinant vector [1 ϫ10 8 (8) pfu] was then delivered over 1 min per injection site. Animals were then given 10 ml of saline sc and allowed to recover. Forty-eight hours later, animals were perfused transcardially with Tyrode solution (132 mm NaCl, 1.8 mm CaCl 2 , 0.32 mm NaH 2 PO 4 , 5.56 mm glucose, 11.6 mm NaHCO 3 , and 2.68 mm KCl), pituitary glands were removed and placed in 4% paraformaldehyde dissolved in 0.1 m PBS for 3 h. Tissue was then paraffin embedded, sectioned using a microtome (5 m) (Leica Corp.), and mounted onto 3-aminopropyltriethoxysilane (APES) (Sigma)-coated glass slides.
Induction of lactotroph hyperplasia and delivery of RAds into the AP gland
Male 8-week-old Buffalo rats were implanted with SILASTIC brand pellets (Dow Corning Corp., Midland, MI) containing 15 mg of 17␤-estradiol and 50 mg of sulpiride, prepared as previously described (22) . The pellets were implanted sc in the lumbar region of each rat under anesthesia. Empty SILASTIC brand pellets were implanted as controls. Three days later, the animals were anesthetized with Fluothane and a total of 1 ϫ 10 8 pfu in 6 l of either RAd35, RAd128 or RAd-PRL/ HSV1-TK was delivered to the anterior pituitary gland as described above. Rats were given a 10ml sc saline injection post surgery, and glucose was added to their drinking water every 2 days to prevent dehydration. One day after surgery, all animals received ip GCV injections at a dose of 25 mg/kg twice daily for 7 days. The animals were killed using a lethal overdose of pentobarbital and perfused with Tyrode's solution. Pituitary, body, and testis weights were recorded. Before perfusion, trunk blood was collected. Pituitary glands were then placed in 4% paraformaldehyde dissolved in 0.1 m PBS for 3 h. Tissue was then paraffin embedded, sectioned using a microtome (5 m), and mounted onto APES-coated glass slides.
Immunohistochemical detection of transgene expression within the anterior pituitary gland in vivo using fluorescence microscopy
Sections were deparaffinated using xylene for 5 min then rehydrated through graded alcohols (100%, 95%, 85%, 70%, 50% ethanol), 3 min each before being washed in saline (0.8% NaCl wt/vol) for 5 min. The blocking solution was prepared using horse serum (10% vol/vol or 1% vol/ vol) diluted in PBS, containing 0.1% Triton X-100. The sections were then incubated in (1): 10% blocking solution for 2 h at room temp (2); 1% blocking solution for 1 h at room temp (3); primary antibody (diluted in 1% blocking solution) for 1 h at room temp (4); five washes in PBS containing 0.5% Triton X-100 for 5 min (5); secondary antibody (diluted in 1% blocking solution) for 1 h at room temp; and (6) five washes in PBS containing 0.5% Triton X-100 for 5 min. The sections were stained with DAPI for 15 min, washed twice in PBS for 5 min, once in dH 2 
Determination of hormone levels in peripheral blood
Rat plasma PRL, GH, and TSH-␤, concentrations were determined using specific RIA kits provided by the National Hormone and Pituitary Program, NIDDK, and Dr A. F. Parlow (Torrance, CA). Plasma ACTH was measured using a specific immunoradiometric assay that has been described previously (23) .
Statistical analysis
The in vitro and in vivo experimental results were analyzed using either ANOVA, followed by the Student's-Neuman-Keuls multiple comparison test or the Student's t test where appropriate, using GraphPad Software, Inc. Instat Version 2 (GraphPad Software, Inc., San Diego, CA).
Results
Construction of adenoviral vectors expressing transgenes under the control of the human PRL promoter
Adenoviral vectors were generated by homologous recombination between the adenoviral genome in pBHG10 and the plasmid p⌬E1sp1a containing the transgenes, i.e. HSV1-TK, or ␤-galactosidase under the control of ϩ14 bp to Ϫ4429 bp or ϩ14 bp to Ϫ4152 bp of the hPrl promoter, respectively, and both followed by the SV40 polyadenylation sequence. The expression construct was inserted within the E1 region of the adenoviral genome. When DNA from these recombinant RAds was digested with HindIII, and probed using Southern blot hybridization, a band of the right size, indicating the presence of the transgenes within the recombinant virus genome, was observed, i.e. the 1406 bp HSV1-TK/ polyA band, the 3257 bp lacZ/polyA band, and the 5000 bp mCMV/lacZ,polyA band (Fig. 1, A-C) .
Cell type-specific expression of ␤-galactosidase within pituitary tumor cell lines, GH3 and AtT20
␤-galactosidase expression was assessed using X-gal histochemical staining, in the GH3 and AtT20 cell lines after infection with RAd36 (mCMV/lacZ), RAd35 (hCMV/lacZ), or RAd-Prl/lacZ. When the cells were infected with RAdPrl/lacZ, only the lactotroph GH3 cells expressed the ␤-galactosidase enzyme (Fig. 2) . No expression of ␤-galactosidase was observed in the corticotrophic AtT20 cell line after infection with RAd-Prl/lacZ. These results show that the PRL promoter can restrict expression of the marker gene ␤-galactosidase to established lactotroph tumor cell lines in vitro.
To quantitate promoter strength from the hCMV, mCMV, and hPrl promoters, within RAds, ␤-galactosidase enzyme activity was assessed in the lactotrophic GH3 cells, and the corticotrophic AtT20 cells following viral infection (Fig. 3) . Both in GH3 cells and AtT20 cells, the levels of enzyme activity increased with increasing MOIs used, of either RAd35 (hCMV/lacZ) or RAd36 (mCMV/lacZ). After infection of GH3 cells with RAd-Prl/lacZ, there was an increase in enzyme activity up to MOI 300. After infection of AtT20 cells with RAd-Prl/lacZ, no enzyme activity above basal levels was observed, even at the highest MOI used, i.e. 300. In GH3 cells, at MOIs 100 and 300, there were 13-and 24-fold more enzyme activity respectively (P Ͻ 0.005), in cells infected with RAd36 when compared with cells infected with RAd35 (Fig. 3) . Levels of transgene expressed under the control of the mCMV promoter in GH3 cells were 46-fold (P Ͻ 0.005) and 70-fold (P Ͻ 0.005) stronger at MOIs of 100 and 300 MOIs (Fig. 3 ) compared with those expressed under the control of the PRL promoter. In AtT20 cells at MOIs 100 and 300, the mCMV promoter was 19-fold (P Ͻ 0.05) and 10-fold (P Ͻ 0.005) stronger than the hCMV promoter (Fig. 3) . In GH3 cells at MOIs 100 and 300, the hCMV promoter was 3-fold (P Ͻ 0.005) stronger than the PRL promoter at both MOIs.
Cell type-specific expression and cytotoxicity of HSV1-TK driven by the hPrl promoter in pituitary tumor cell lines
The expression of HSV1-TK driven by the hPrl promoter was also assessed in both GH3 and AtT20 cells using immunofluorescence microscopy (Fig. 4) . Infection of these cells with RAd-Prl/HSV1-TK resulted in a strong immunocytochemical staining in the lactotrophic GH3 cells; there was no increase, above basal levels, of apoptotic nuclei at the concentration of virus used (MOI 30) (Fig. 4) . In AtT20 cells, we observed no HSV1-TK transgene expression (Fig. 4) .
To quantitate the levels of HSV1-TK expression with increasing viral dose in AtT20 and GH3 cells, they were infected for 48 h with RAd-Prl/HSV1-TK, using MOIs ranging from 0 -100. Figure 5A shows a gradual increase in HSV1-TK immunoreactivity, as detected by flow cytometry in the GH3 cell line only. The level of HSV1-TK immunoreactive protein was maximal at MOI 100 in the GH3 cells. HSV1-TK expression remained at basal levels in AtT20 cells at all MOIs tested (Fig. 5A) .
Infection of GH3 cells with RAd-Prl/HSV1-TK in the presence of 10 m GCV induced apoptosis, which was MOI dependent (Fig. 5B) . In the presence and absence of GCV (10 m), even at the highest MOI of RAd-Prl/HSV1-TK used, only basal levels of apoptosis were observed in AtT20 cells indicating there was no HSV1-TK mediated toxicity (Fig. 5C ).
Cell type-specific expression of transgenes expressed under the transcriptional control of the hPrl promoter in rat primary anterior pituitary cell cultures and in the anterior pituitary gland in vivo
When rat primary anterior pituitary cultures were infected with RAd-Prl/HSV1-TK the expression of HSV1-TK was mainly restricted to cells expressing PRL (Prl) (89% Ϯ 7 of cells expressing HSV1-TK also expressed PRL) (Fig. 6 and Table 1 ), and a subset of GH-producing cells (11% Ϯ 0.8 of total HSV1-TK immunoreactive cell population also expressed GH) (Fig. 6 and Table 1 ). Transgene expression under the control of the hPrl promoter was achieved in 60% Ϯ 6.9 of the total lactotrophic population in anterior pituitary cells in vitro. Expression of the transgene HSV1-TK also observed in the 9% Ϯ 0.9 of the total somatotrophic population possibly representing the subpopulation of cells that coexpress PRL and GH, i.e. mammosomatotrophs. No expres- sion of HSV1-TK was observed in cells synthesizing FSH, LH, TSH, or ACTH. There was no indication of apoptosis as assessed by the nuclear integrity after DAPI staining (Fig. 6) .
To determine the specificity of the hPrl promoter in the anterior pituitary gland in vivo, we compared the cell populations expressing HSV1-TK driven by the hPrl promoter, the hCMV, or the mCMV promoters. All recombinant adenovirus vectors drove transgene expression in the anterior pituitary gland in vivo (Figs. 7 and 8 and Table 2 ). The mCMV and the hCMV promoters drove transgene expression of either HSV1-TK or ␤-gal in all endocrine cell populations encountered within the anterior pituitary gland (Figs. 7 and 8 and Table 2 ). However, the hPrl promoter restricted expression of HSV1-TK almost exclusively to Prl expressing cells (approximately 50% of the lactotrophic population within the transduced area expressed the transgene) ( Fig. 8 and Table 2 ). A small number of GH immunoreactive cells were also HSV1-TK immunoreactive (0.5-1% of total GH immunoreactive cells). These cells are likely to be mammosomatotrophs. There was no indication of apoptosis in the normal pituitary glands infected with any of the recombinant adenovirus vectors as assessed by the nuclear integrity after DAPI staining and microscopic examination of all endocrine cell populations (results not shown).
In vivo gene therapy of oestrogen/sulpiride induced lactotroph hyperplasia using HSV-1 TK under the control of either the hCMV or the hPrl promoter in combination with GCV
In control placebo-treated animals, PRL immunoreactive cells comprised 18 Ϯ 1% of the total pituitary cell population within the transduced area (Table 2) , whereas in the E/Simplanted animals treated with RAd35/GCV, the population rose to 23 Ϯ 0.5% of the total cell population within the area of the anterior pituitary, which had been transduced by the vector (P Ͻ 0.005 vs. control). In the E/S-implanted animal group treated with RAd128/GCV, we observed a decrease in the PRL producing cell population to 15 Ϯ 1% of the total cell population (P Ͻ 0.05 vs. E/S implanted, RAd35/ GCV-treated group) ( Table 2 ). There was no change in the number of PRL positive cells in E/S implanted animals treated with RAd-Prl/HSV1-TK. There were no significant changes in GH, FSH, LH, ACTH, or TSH-␤ cell populations in any of the treated animal groups with respect to controls ( Table 2) .
Pituitary weight in control animals averaged 11.3 Ϯ 0.5 mg. whereas the E/S implanted animals treated with RAd35/GCV had a mean pituitary weight of 22.7 Ϯ 1.3 mg (P Ͻ 0.0005 vs. controls). The E/S implanted group treated with RAd128/GCV had an average pituitary weight of 18.7 Ϯ 0.5 mg, an 18% reduction when compared with the E/S implanted RAd35/GCV treated group (P Ͻ 0.05). The E/S implanted group treated with RAd-Prl/HSV1-TK/GCV had pituitary weight of 22.9 Ϯ 0.3 mg (not significant vs. E/S implanted group treated with RAd35/GCV).
Plasma Prl in placebo-implanted control rats was 38 Ϯ 4 ng/ml, whereas in the E/S-implanted group treated with RAd35 and GCV, circulating Prl levels increased to 660 Ϯ 28.3ng/ml. In the E/S implanted group treated with RAd128 and GCV, Prl levels were reduced to 330 Ϯ 50.1ng/ml (P Ͻ 0.005 vs. E/S implanted RAd35/GCV treated group), a reduction of 50% (Fig. 9 ). In the E/S-implanted group treated with RAd-Prl/HSV1-TK and GCV, Prl levels were not significantly reduced. No changes were observed in circulating ACTH, GH, and TSH-␤ levels in any of the experimental groups (Fig. 9) .
Discussion
An advantage of gene therapy, in comparison with classical pharmacology, is the capacity to selectively modulate the genetic makeup and function of identified pituitary cell subtypes, while leaving surrounding pituitary cells of other phenotypes unaffected (24) . This will be of particular importance when targeting cytotoxic proteins to tumoral cell types for the purpose of eliminating tumors, while leaving the surrounding normal pituitary intact. The use of pituitary cell type specific promoters has been proposed to constitute a molecular tool to achieve pituitary cell type-specific transcriptional targeting of virally encoded transgenes (2, 3) .
Our results indicate that the human PRL promoter encoded within recombinant adenovirus vectors can restrict transgene expression, e.g. HSV1-TK or ␤-galactosidase, exclusively to lactotrophic cells both in vitro and in vivo. The restriction of expression of HSV1-TK to lactotrophic cells, using the PRL promoter, resulted in the cell type-specific induction of apoptosis in the lactotrophic tumor GH3 cell line, in the presence of GCV. In the corticotrophic AtT20 cell line, there was neither HSV1-TK expression, nor apoptosis in the presence of GCV, even at an MOI 100. Therefore, the human PRL promoter is able to target the expression of HSV1-TK to lactotroph tumor cells.
The measurement of ␤-galactosidase enzyme activity levels enabled us to quantitate and compare the levels of transgene expression directed by either the PRL promoter, or the constitutive mCMV or hCMV promoters. The mCMV promoter has been reported to be stronger in a variety of human and murine immortalized cell lines in vitro (25) or in the brain in vivo (26) . Of the three promoters tested, i.e. hCMV, mCMV, and hPrl, the mCMV elicited the highest levels of transgene expression in both pituitary tumor cell lines. In GH3 cells, the Hormone-producing cells were stained for the various hormones and analyzed for the coexpression of HSV1-TK whose expression was driven by the human PRL promoter after infection with RAd-PRL/ HSV1-TK. Note that out of the total HSV1-TK immunoreactive cell population, 89 Ϯ 7% coexpressed HSV1-TK and prolactin and 11 Ϯ 0.8% coexpressed GH and HSV1-TK. Ten fields were counted under ϫ40 magnification in the area of transduction.
FIG. 7. Expression of ␤-galactosidase within endocrine cell populations after in vivo delivery to the anterior pituitary gland of 6 ϫ10 8 pfu of RAd35 or RAd36. After 48 h infection, the pituitaries were removed, embedded in paraffin wax, sectioned, and stained for hormone and ␤-galactosidase immunoreactivity using double-labeling immunofluorescence techniques. RAd35 (left panels), RAd36 (right panels) infection resulted in the expression of ␤-galactosidase in all endocrine cell populations. Low magnification images (ϫ100) top panels show widespread distribution of ␤-galactosidase expression within the AP gland and, high magnification images (ϫ500) show colocalization of hormone-producing cells expressing ␤-galactosidase as indicated at the bottom of the panels. White arrows indicate cells that are labeled for both the hormone and ␤-galactosidase. mCMV promoter elicited approximately 50-fold higher expression when compared with the hPrl promoter.
The strength of the promoter used would determine the amount of virus needed to achieve a therapeutic effect. By using a stronger promoter, less virus would be needed to achieve adequate levels of transgene expression (25, 26) . This would therefore reduce toxic side effects due to high doses of viral vector that have been previously shown to cause acute cytotoxicity (27) as well as chronic inflammation in the brain (10) .
Our work has shown that sequences ϩ14 bp to Ϫ4152 bp or Ϫ4429 bp of the human PRL promoter can restrict transgene expression from an adenoviral vector to lactotrophic cells in primary anterior pituitary cultures and importantly within the anterior pituitary gland in vivo. However, transgene expression was also detected in a subpopulation of GH expressing cells both in primary culture and in vivo. These cells are probably mammosomatotrophs, which are thought to be the transitional intermediates of lactotrophs and somatotrophs (28) , and synthesize both GH and PRL. Lee et al. (1999) , (3) have recently shown that the GH and the ␣-glycoprotein subunit promoters could restrict the expression of transgenes to somatotroph and null-cell tumor cell lines, respectively. They also showed that the size of sc tumors, derived from implanted GH3 cells in nude mice, could be reduced by the delivery of an adenovirus expressing HSV1-TK, under the control of the GH promoter, when combined with the administration of GCV (3). We decided to explore the in vivo delivery of HSV1-TK driven by the human PRL promoter encoded within recombinant adenovirus vectors to the anterior pituitary in a rat model of estrogen/sulpiride induced pituitary hyperplasia. This enabled us to demonstrate for the first time that, although the human PRL promoter is able to restrict transgene expression mainly to lactotrophic cells within the anterior pituitary gland in vivo, the level of expression of the therapeutic transgene (HSV1-TK) was not sufficient to achieve a measurable therapeutic outcome.
In contrast, the ubiquitous hCMV promoter driving expression of HSV1-TK, which we used as a positive control for this experiment, was able to elicit a beneficial therapeutic outcome. This confirms our previous results showing that FIG. 9 . Changes in circulating hormone levels following in vivo gene therapy treatment in an estrogen/sulpiride (E/S) implanted in vivo model. Plasma was analyzed for Prl, GH, and TSH levels using specific RIAs (9) . The ACTH levels were analyzed using a specific IRMA (23) . The various hormone levels for the E/S implanted RAd128/GCV, RAd-PRL/HSV1-TK/GCV and RAd35/ GCV-treated groups were compared by fold increase above the control hormone levels in placebo implanted animals. *, P Ͻ 0.005. delivery of HSV1-TK driven by the hCMV promoter to rats bearing estrogen-induced lactotroph hyperplasia, into the AP gland via the transauricular route followed by subsequent treatment with GCV decreased plasma PRL levels and reduced the mass of the pituitary gland (9) . Neither RAdPrl/HSV1-TK nor RAd-hCMV/HSV1-TK (RAd128) caused deleterious effects on circulating levels of other anterior pituitary hormones, suggesting that the treatment was nontoxic to the normal endocrine anterior pituitary cells in situ (9) , although hormone secretion in response to secretagogues was not tested. Even if the hCMV promoter is not specific to the hyperplasic lactotrophic cells, its toxic effects ought to be restricted to those cells, which are actively dividing. In the estrogen/sulpiride model used, only lactotrophic cells are actively dividing. Although the hCMV promoter has no celltype specificity, in our model only the lactotrophic cells are eliminated, due to the molecular mechanism of cell killing of HSV1-TK in combination with GCV, which only affects actively dividing cells.
The lessons to be learned from the in vivo experiment described in this paper are very important, not only in terms of the implications for the development of gene therapy strategies for pituitary disease, but also for gene therapy in general. Although cell type-specific promoters are efficient in restricting transgene expression to predetermined cell types, in this case such a promoter was not strong enough to produce a beneficial therapeutic outcome. Furthermore, a nonspecific promoter used in conjunction with a cell killing mechanism that selectively kills actively dividing cells, provided the restricted elimination of hyperplasic lactotroph pituitary cells, without adversely affecting other pituitary cell types.
Our results contrast with those published previously showing tumor regression in a GH transplantable tumor model in nude mice (3) . We believe the different results depend on the particular model used. The transplantable model employs a very rapidly growing tumor in which HSV1-TK would elicit a very strong effect. We believe that our model represents more closely the situation that would be encountered in a human pituitary tumor in which the proliferative index is low. Because the efficiency of the HSV1-TK plus GCV system depends on both the efficiency of virus transduction and the rate of cell proliferation, we predict higher levels of HSV1-TK expression to be required to efficiently reduce lactotrophic cells' proliferation and PRL hypersecretion in our in situ tumor model. This explains, why HSV1-TK expressed under the control of the hCMV promoter, but not, under control of the hPrl promoter, showed a significant therapeutic benefit. Again our results indicate the importance of properly designed preclinical studies before these therapeutic approaches are taken into the clinic.
